BMS sues over generic of blockbuster leukaemia treatment
04-10-2021
BMS boosts cardio portfolio with $13bn buy
06-10-2020
FDA approves Dr Reddy’s Vascepa generic
13-08-2020
Bristol-Myers Squibb to acquire Celgene in $74bn deal
03-01-2019
Katherine Welles / Shutterstock.com
Bristol Myers Squibb (BMS) and Celgene have settled their patent litigation with Dr Reddy’s over a generic version of cancer drug Revlimid (lenalidomide).
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Bristol Myers Squibb, BMS, Celgene, Dr Reddy’s, Revlimid, lenalidomide, generics, settlement, cancer, oncology
